Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merits of making (a) rozanolixizumab, (b) zilucoplan and (c) efgartigimod available to NHS patients with myasthenia gravis (MG); and what (i) representations his Department has received from and (ii) meetings his Department has had with MG patients on that matter.

The Department has made no such assessment. The National Institute for Health and Care Excellence (NICE) makes evidence-based recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. The NICE is currently evaluating rozanolixizumab, zilucoplan, and efgartigimod within their licensed indications for the treatment of myasthenia gravis, and has not yet published final guidance.

The Department has received correspondence letters from constituents via their Member of Parliament regarding myasthenia gravis and the treatment for this condition, but there have not been any recent meetings between Ministers and patients with this condition.